You are here
P&T News
June 25
Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
June 20
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Results Could Have Major Impact on Treatment Costs
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile
June 18
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
June 13
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
June 11
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications
June 6
Nivolumab/Chemotherapy Arm Shows No Unexpected Toxicities
Phase 2 Trial To Begin in 2020
“Baltimore Score” Outperforms Existing Prediction Models
Nexus Has Increased Power, RF Capabilities
Patients Had 8+ Fewer Weekly Attacks
June 5
Benefit Seen After 3 Years of Continuous Use
New Indication for Ceftolozane/Tazobactam Injection
ASCO Results Exceed Researchers’ Expectations
22% of Patients Progression-Free Two Years Later